Helping Patients Tomorrow by Helping Patients Today
Why Now?
Every day thousands of patients die from aging-associated non-communicable diseases (AA-NCDs). AA-NCDs have been recognized by the United Nations as a “threat to global development.” and a mandate has been set to improve the consequences of such diseases. Helping patients get access to new therapeutics is BCM’s primary objective.
Make it happen.
Their Future Depend On The Decisions of Today
Giving Patients the Dignity to Live Healthier Lives
The BCM plan proposed here could give millions of patients access to technological advancements earlier in drug development than current legislation allows and enable biotech companies to legally do first-in-human studies based on patient consent and a medical doctor’s approval to treat.
“Numerous patients have fought for the legal authority to try new medicines, as seen in the "Right to Try Act" legislation; alas, these laws do not cover newer and more precise genetic therapies which are not currently in clinical trials. A new regulatory designation Regenerative Medicine Advanced Therapy (RMAT) addresses regenerative medicine but not early access to the treatments in the ever-demanding aging patient population”
— Parrish EL, Andrews WH. A “Best Choice Medicine” (BCM) Route to Drug Development to Solve the Aging-Associated Non-Communicable Disease Burden. J Biomed Allied Res. 2022;4(1):1-116. DOI: https://doi.org/10.37191/Mapsci-2582-4937-4(1)-025
Helping People Takes New Laws & Stakeholder Approval
Give those in need a helping hand!
Please read our peer-reviewed paper - A “Best Choice Medicine” (BCM) Route to Drug Development to Solve the Aging-Associated Non-Communicable Disease Burden